Allelix, Trophix deal

The companies signed a letter of intent under which AXB will acquire Trophix, a developer of drugs to treat neurological

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE